Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22246410 | 0.90 | ADORA2A (0.59) | ADORA2APDE3BPDE3ACNR1CNR2 | |
| SCHEMBL22251152 | 0.87 | ADORA2A (0.52) | ADORA2ACYP11B2ADORA2B | |
| SCHEMBL22246481 | 0.86 | ADORA2A (0.49) | ADORA2APDE3BPDE3ACNR1CNR2 | |
| SCHEMBL22246418 | 0.85 | ADORA2A (0.69) | ADORA2APDE3BPDE3A | |
| SCHEMBL22246475 | 0.84 | ADORA2A (0.48) | ADORA2APDE3BPDE3ACNR1CNR2 | |
| SCHEMBL22246474 | 0.84 | ADORA2A (0.46) | ADORA2APDE3BPDE3ACNR1CNR2 | |
| SCHEMBL22246317 | 0.83 | ADORA2A (0.47) | ADORA2APDE3BPDE3ACNR1CNR2 | |
| SCHEMBL22246457 | 0.83 | ADORA2A (0.75) | ADORA2ADYRK1B | |
| SCHEMBL22246300 | 0.83 | ADORA2A (0.55) | ADORA2A | |
| SCHEMBL22246413 | 0.82 | ADORA2A (0.47) | ADORA2APDE3BPDE3ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169648-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-06-02 | — | — | US | disclosed |
| US-11254670-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200231589-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-23 | — | — | US | disclosed |
| WO-2020150676-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254670-B2 | 1,8-naphthyridinone compounds and uses thereof | NME1, ADORA2A, GPR68 | ADORA2A 2/4885PDE3B 557/4885PDE3A 398/4885 |
| US-20200231589-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | ADORA2A 2/4885PDE3B 557/4885PDE3A 398/4885 |
| US-20220169648-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | ADORA2A 2/4885PDE3B 557/4885PDE3A 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.